72 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
-effective paths to market,” added Melissa Tosca, EVP Finance. “For 2024, we expect to increase our R&D spend, with expenses for KIO-301 offset by quarterly … of patients in Phase 2 clinical trials, with trial-related expenses for KIO-301 offset by reimbursement from TOI.
General and administrative expenses
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
30 Apr 21
Additional proxy soliciting materials
4:07pm
:
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
29 Apr 20
Additional proxy soliciting materials
4:16pm
:
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
2 May 19
Additional proxy soliciting materials
7:38am
:
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
DEFA14A
KPRX
Kiora Pharmaceuticals Inc
29 May 18
Additional proxy soliciting materials
4:32pm
:
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
8-K
EX-99.1
m9yk1bj2fd032
8 Aug 23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
7:14am
DEFA14A
j2wk3gg
3 Jul 18
Additional proxy soliciting materials
4:15pm